A Multicenter, Open-Label, Randomized Controlled Phase 3 Study of Tislelizumab Monotherapy Versus Salvage Chemotherapy in Patients With Relapsed/Refractory Classical Hodgkin Lymphoma

Status: Recruiting

Phase of Trial: Phase III

Latest Information Update: 01 Jan 2025

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Tislelizumab (Primary) ; Carboplatin; Cisplatin; Cytarabine; Dexamethasone; Doxorubicin; Etoposide; Gemcitabine; Ifosfamide; Mesna; Methylprednisolone; Mitoxantrone; Prednisone; Vinorelbine
Indications Hodgkin's disease
Focus Registrational; Therapeutic Use
Sponsors BeiGene

13 Dec 2024 Planned End Date changed from 26 Mar 2025 to 28 Feb 2026.
13 Dec 2024 Planned primary completion date changed from 26 Sep 2024 to 28 Feb 2026.
25 Feb 2021 According to a BeiGene media release, first patient has been dosed in this trial.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com